Cargando…
Antiphospholipid syndrome in systemic autoimmune diseases /
Antiphospholipid Syndrome in Systemic Autoimmune Diseases, Second Edition provides an overview of our current understanding of this major disease. It includes the latest information on the new pathogenetic mechanisms involved, along with clinical manifestations in both the thrombotic and non-thrombo...
| Clasificación: | Libro Electrónico |
|---|---|
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Amsterdam ; Boston :
Elsevier,
[2016]
|
| Edición: | Second edition. |
| Colección: | Handbook of systemic autoimmune diseases ;
v. 10. |
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn952155566 | ||
| 003 | OCoLC | ||
| 005 | 20231120112117.0 | ||
| 006 | m o d | ||
| 007 | cr |n||||||||| | ||
| 008 | 160624s2016 ne ob 001 0 eng d | ||
| 040 | |a IDEBK |b eng |e pn |c IDEBK |d YDXCP |d N$T |d EBLCP |d OCLCQ |d OCLCF |d OPELS |d OCLCQ |d OTZ |d OCLCQ |d U3G |d CASUM |d OCLCO |d MERER |d OCLCO |d D6H |d DKU |d OCLCQ |d U3W |d NLE |d UKMGB |d AU@ |d OCLCQ |d OCLCO |d OCLCQ |d OCLCA |d OPELS |d OCLCQ |d OPELS |d S2H |d OCLCO |d OCLCQ |d OCLCO |d OCLCQ | ||
| 066 | |c (S | ||
| 015 | |a GBB6I9877 |2 bnb | ||
| 015 | |a GBB753036 |2 bnb | ||
| 016 | 7 | |a 018003245 |2 Uk | |
| 016 | 7 | |a 017549422 |2 Uk | |
| 019 | |a 952248259 |a 987027203 |a 989383260 | ||
| 020 | |a 0444636560 |q (electronic bk.) | ||
| 020 | |a 9780444636560 |q (electronic bk.) | ||
| 020 | |a 9781282954250 | ||
| 020 | |a 1282954253 | ||
| 020 | |a 9786612954252 | ||
| 020 | |a 6612954256 | ||
| 020 | |a 9780080932347 | ||
| 020 | |a 0080932347 | ||
| 020 | |a 9780444531698 | ||
| 020 | |a 0444531696 | ||
| 020 | |a 9780444636553 |q (electronic bk.) | ||
| 020 | |a 0444636552 |q (electronic bk.) | ||
| 035 | |a (OCoLC)952155566 |z (OCoLC)952248259 |z (OCoLC)987027203 |z (OCoLC)989383260 | ||
| 050 | 4 | |a RC600 | |
| 072 | 7 | |a HEA |x 039000 |2 bisacsh | |
| 072 | 7 | |a MED |x 014000 |2 bisacsh | |
| 072 | 7 | |a MED |x 022000 |2 bisacsh | |
| 072 | 7 | |a MED |x 112000 |2 bisacsh | |
| 072 | 7 | |a MED |x 045000 |2 bisacsh | |
| 082 | 0 | 4 | |a 616.978 |2 23 |
| 245 | 0 | 0 | |a Antiphospholipid syndrome in systemic autoimmune diseases / |c edited by Ricard Cervera, Gerard Espinosa, Munther Khamashta. |
| 250 | |a Second edition. | ||
| 260 | |a Amsterdam ; |a Boston : |b Elsevier, |c [2016] | ||
| 300 | |a 1 online resource | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Handbook of systemic autoimmune diseases ; |v volume 10 | |
| 490 | 0 | |a Handbook of Systemic Autoimmune Diseases ; |v 12 | |
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Front Cover; Antiphospholipid Syndrome in Systemic Autoimmune Diseases; Copyright Page; Contents; List of Contributors; Foreword; Dedication; 1 History, Classification, and Subsets of the Antiphospholipid Syndrome; 1.1 Introduction; 1.2 Historical Perspective; 1.3 Classification of APS; 1.4 Primary or Isolated APS; 1.5 APS Associated With Other Diseases; 1.5.1 APS Associated With Autoimmune Diseases; 1.5.2 APS Associated With Infections; 1.5.3 APS Associated With Drugs; 1.5.4 APS Associated With Malignancies; 1.6 Seronegative APS; 1.7 Catastrophic APS; 1.8 International aPL/APS Congresses. | |
| 505 | 8 | |6 880-01 |a 4.2.4 Antiprothrombin Antibodies4.2.5 Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin; 4.2.6 Antibodies to Phosphatidylethanolamine; 4.2.7 Other aPL Specificities; 4.3 Lupus Anticoagulant; 4.4 Annexin A5 Resistance Test: A Mechanistic Test for the Detection of Pathogenic aPL Antibodies; 4.5 New Technologies for the Detection of aPL; 4.6 Which aPL Should Be Tested in Patients With Suspicion of Having APS?; 4.7 Conclusions; Acknowledgements; References; 5 Genetic and Epigenetic Aspects of Antiphospholipid Syndrome; 5.1 HLA, APS, and aPL; 5.1.1 Family Studies. | |
| 520 | |a Antiphospholipid Syndrome in Systemic Autoimmune Diseases, Second Edition provides an overview of our current understanding of this major disease. It includes the latest information on the new pathogenetic mechanisms involved, along with clinical manifestations in both the thrombotic and non-thrombotic manifestations of this important disease. Antiphospholipid syndrome is an autoimmune disease that causes abnormal blood clots. It is now recognized as a major cause of common conditions, including stroke, heart attack, miscarriage, epilepsy, and memory loss, and as such is gaining recognition in all branches of medicine, from obstetrics to cardiology, and from psychiatry to orthopedics. | ||
| 650 | 0 | |a Antiphospholipid syndrome. | |
| 650 | 1 | 2 | |a Antiphospholipid Syndrome |0 (DNLM)D016736 |
| 650 | 6 | |a Syndrome antiphospholipide. |0 (CaQQLa)201-0286017 | |
| 650 | 7 | |a HEALTH & FITNESS |x Diseases |x General. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Clinical Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Diseases. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Evidence-Based Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Internal Medicine. |2 bisacsh | |
| 650 | 7 | |a Antiphospholipid syndrome. |2 fast |0 (OCoLC)fst00810662 | |
| 655 | 4 | |a Internet Resources. | |
| 700 | 1 | |a Cervera, Ricard. | |
| 776 | 0 | 8 | |i Print version: |a Cervera, Ricard. |t Antiphospholipid Syndrome in Systemic Autoimmune Diseases. |d Saint Louis : Elsevier Science, �2016 |z 9780444636553 |
| 830 | 0 | |a Handbook of systemic autoimmune diseases ; |v v. 10. | |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/handbooks/15715078/12 |z Texto completo |
| 880 | 8 | |6 505-01/(S |a 3.3.1 Endothelial Cells3.3.2 Monocytes; 3.3.3 Platelets; 3.3.4 Neutrophils; 3.3.5 Soluble Phase; 3.3.6 Complement; 3.4 aPL-Mediated Mechanism of Pregnancy Complications; 3.5 Receptors for β2GPI/Anti-β2GPI Antibodies; 3.6 Intracellular Pathways; 3.7 Two-Hit Hypothesis; 3.8 Genetics and Epigenetics; 3.9 Conclusions; References; 4 Laboratory Markers With Clinical Significance in the Antiphospholipid Syndrome; 4.1 Introduction; 4.2 aPL Detected by Solid-Phase Immunoassays; 4.2.1 Anticardiolipin Antibody Assay; 4.2.2 Anti-β2GPI Antibody Assay; 4.2.3 Antibodies Against Domain I of β2GPI. | |